Canopy Growth crushed estimates during the third quarter, and it could be just the beginning of a rebound.
Despite only having one product on the market, Intercept Pharmaceuticals is worth considering.
After a forgettable first nine months as a publicly traded company, is Uber finally ready to live up to the lofty expectations?
It looks like Spotify is making the right moves.
Aurora Cannabis has faced a slate of issues recently, but do they represent a buying opportunity?
Apple TV+ isn't keeping up with the competition.
Keytruda will continue to be a growth driver for Merck, but the company is looking elsewhere for growth as well.
Despite poor performances in recent years, here's why Gilead Sciences could turn things around.
Here's why investors might want to swipe right on Match.
Can OrganiGram maintain its momentum?
Despite Humira's declining international sales, AbbVie is still worth considering.
Should investors worry about Epidiolex's slowing sales growth?
An increasingly competitive landscape could derail Snap's comeback story.
The iPhone maker isn't done growing just yet.
The acquisition of Celgene is working wonders so far.
The food allergy specialist just landed its first approval.
Investors should overlook PayPal's weak guidance for 2020.
Facebook’s recent slump isn’t the end of the world.
Despite slow revenue growth, the healthcare company has much to offer investors.
What does the future hold for these two biotech stocks?